文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > imatinib

imatinib

  • Adjuvant imatinib Treatment after R0 Resection for Patients With High-Risk

    JournalofSurgicalOncologyAdjuvantImatinibTreatmentafterR0ResectionforPatientsWithHigh-RiskGastrointestinalStromalTumors:AMedianFollow-Upof44M...

  • imatinib Mesylate_220127-57-1_CoA_MedChemExpress

    Certificate of AnalysisProductName:Product Name:ImatinibMesylateImatinib MesylateFormula:MolWeight:CAS No.:Cat. No.:Batch No:Test Date:Retest Date:C30H35N7O...

  • and Review of the Literature

    Case Report510Imatinib-Induced Tumor Lysis Syndrome: Report of a Caseand Review of the LiteratureHung Chang, MD; Lee-Yung ...

  • 212 Mechanisms of secondary resistance to tyrosine kinase i

    ...apy and conventional chemo-therapy (2). No effective medical treatment was available until2001 when imatinib mesylate (Gleevec®) was successfullyintroduced to treat advanced unresectable GISTs (3). Thede...

  • Cancer-drug discovery and cardiovascular surveillance

    ...d tyrosine kinase inhi-bition as a model for cancer-drug discovery and therapy in general. In 2001, imatinib became the first such tyrosine kinase inhibi-tor therapy to be approved by the Food and Drug Admini...

  • A Novel Second-line__ Tyrosine-kinase-inhibitor Involving Regimen for Promyelocytic Blast Crisis__ o

    ...e-inhibitor Involving Regimen for Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia During Imatinib Treatment with RT-PCR and FISH AnalysisRunning titleDasatinib for Promyelocytic Blast Crisis of CML...

  • Nilotinib_641571-10-0_DataSheet_MedChemExpress

    ...s with Philadelphia chromosome–positive chronic myelogenouspppygleukemia in chronic phase following imatinib resistance and intolerance Blood November 15, 2007vol. 110 no. 103540-3546[3]. Sevinc A.Activity of...

  • Flumatinib mesylate_895519-91-2_DataSheet_MedChemExpress

    ...rotein Tyrosine Kinase/RTK; Target:Bcr-AblBiological Activity:Flumatinib (HHGV678) ,a derivative of imatinib, is a multikinase inhibitor with IC50 Values of 1.2Flumatinib(HH-GV-678)aderivativeofimatinib,isamu...

  • 伊马替尼耐药的K562细胞系的建立及其生物学特性研究

    337 论著 伊马替尼耐药的K562细胞系的建立及其生物学特性研究齐静 彭晖 顾振纶 梁中琴 杨纯正  【摘要】 目的 体外建立一株对伊马替尼(imatinib)耐药的白血病细胞并阐明其生物学特性。方法 以药物浓度递增的方法诱导人白血病细胞株K562对伊马替尼产生耐药性,以MTT法确定其耐药倍数及抗药谱。用RT2PCR和Westernblot方法检测耐药细胞...

  • 国际多中心伊马替尼治疗慢性髓性白血病随机研究8年随访进展_肖志坚

    ...)属于多能造血干细胞恶性骨髓增生性疾病,费城(Ph)染色体是CML的细胞遗传学标志,90%以上CML患者骨髓细胞中发现有Ph染色体。经过20年的研究,CML患者的生存预后得到显著改善,特别是伊马替尼(imatinib,商品名格列卫)成功应用于临床治疗CML。伊马替尼是酪氨酸激酶抑制剂,目前是CML慢性期(CML CP)最有效的靶向治疗药物。2009年ASH年会上报告了伊马替尼用于CML一线治疗的IRIS研究(国...

  • Chronic myeloid leukaemia a seminar

    ...that far exceeds that expected from its frequency, and serves as a model disease for other cancers. Imatinib, an inhibitor of BCR-ABL tyrosine kinase, has revolutionised treatment of this disease, and is now ...

    最近文档搜索:

      站点地图 | 文档上传 | 侵权投诉 | 手机版
      本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
      文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email